Generic Name and Formulations:
Rifapentine 150mg; tabs.
Indications for PRIFTIN:
Susceptible active pulmonary tuberculosis. Latent tuberculosis infection in patients ≥2yrs old at high risk of progression to tuberculosis disease.
Limitations Of use:
Active: not for monotherapy use in either phases. Latent: rule out active tuberculosis disease before treatment initiation.
Adults and Children:
Take with food. If unable to swallow tabs: may crush and add to semi-solid food. Active TB: <12yrs: not established. ≥12yrs: Initial phase: 600mg twice weekly for 2 months, with an interval of no less than 3 consecutive days (72hrs) between doses, in combination with other antituberculosis drugs (eg, isoniazid, ethambutol, pyrazinamide); Continuation phase: Following Initial phase, 600mg once weekly for 4 months in combination with isoniazid or an appropriate antituberculosis agent. Latent TB: <2yrs: not established. Give once weekly in combination with isoniazid (see full labeling for dosage) for 12 weeks. ≥2yrs: (10–14kg): 300mg; (14.1–25kg): 450mg; (25.1–32kg): 600mg; (32.1–50kg): 750mg; (>50kg): 900mg. Max 900mg once weekly.
HIV seropositive patients: Initial Phase treatment regimen has not been studied, also do not use once weekly Continuation Phase regimen in combination with isoniazid; higher rate of failure and/or relapse with presence of rifampin-resistant organisms. Cavitary pulmonary lesions and/or positive sputum cultures after initial phase of treatment, bilateral pulmonary disease, poor compliance, HIV positive patients: higher rates of relapse. Hepatic impairment: obtain serum transaminase levels prior to and every 2–4 weeks during therapy; discontinue if liver disease occurs or worsens. Monitor for hypersensitivity reactions; discontinue if occur. Porphyria: not recommended. May discolor body tissue/fluids, contacts and dentures may become permanently stained. Pregnancy (Cat.C). Nursing mothers: not recommended.
May antagonize protease inhibitors, reverse transcriptase inhibitors (significant decrease in plasma concentrations and loss of therapeutic effect), antiarrhythmics (eg, disopyramide, mexiletine, quinidine, tocainide), antibiotics (eg, chloramphenicol, clarithromycin, dapsone, doxycycline, fluoroquinolones), oral anticoagulants (eg, warfarin), anticonvulsants (eg, phenytoin), antimalarials (eg, quinine), azole antifungals (eg, fluconazole, itraconazole, ketoconazole), antipsychotics (eg, haloperidol), barbiturates (eg, phenobarbital), benzodiazepines (eg, diazepam), β-blockers (eg, propranolol), calcium channel blockers (eg, diltiazem, nifedipine, verapamil), cardiac glycoside preparations (eg, digoxin), corticosteroids (eg, prednisone), fibrates (eg, clofibrate), oral hypoglycemics (eg, sulfonylureas), hormonal contraceptives (eg, ethinyl estradiol, levonorgestrel), immunosuppressants (eg, cyclosporine, tacrolimus), theophylline, methadone, PDE-5 inhibitors (eg, sildenafil), levothyroxine, tricyclic antidepressants (eg, amitriptyline, nortriptyline). May inhibit standard assays for serum folate and Vit. B12; use alternative method.
Lymphopenia, neutropenia, anemia, increased ALT, arthralgia, conjunctivitis, headache, vomiting, nausea, diarrhea, rash, pruritus, anorexia, lymphadenopathy, hypersensitivity reactions; hepatotoxicity, C. difficile-associated diarrhea.
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Methadone Improves Short-Term Outcomes Better Than Morphine in Neonatal Abstinence Syndrome
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Hospital-Owned Practices Associated With Positive Workplace Perceptions Among Staff
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Chinese Traditional Medicine Showed Effectiveness on Pain, Quality of Life in Advanced Cancer